Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

 
• By Cathy Kelly
  
Demonstrating The Value Of The Drug To Its Leading Prospective Payer • Source: Shutterstock

More from Market Access

More from Pink Sheet